It's fortunate that Pfizer/BioNTech chose the whole spike protein mRNA as their vaccine candidate over the one that focused just on the receptor binding domain -- which the UK mutation changed. Wise choice, and hopefully it will work well against this new variant.
https://www.nejm.org/doi/full/10.1056/NEJMoa2027906
Moderna's vaccine was focused on the whole spike protein too. So even though there are crucial mutations in this mutation, both leading vaccine candidates hopefully will still be effective.
Moderna's vaccine was focused on the whole spike protein too. So even though there are crucial mutations in this mutation, both leading vaccine candidates hopefully will still be effective.